Single-dose bladder chemotherapy after diagnostic scope for upper urinary tract cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether giving a single dose of chemotherapy directly into the bladder right after a diagnostic scope procedure can help prevent the cancer from coming back in people with a new diagnosis of cancer in the kidney or ureter. It is an extra step that may reduce the risk of recurrence without delaying standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with a localized cancer in the kidney or ureter (upper tract urothelial cancer) that has not spread.
- You must agree to receive one dose of chemotherapy solution into the bladder after the diagnostic procedure (ureteroscopy).
- You must be willing to follow the standard treatment and follow-up care your doctor recommends.
- You should not have had bladder cancer in the last 5 years, or currently have bladder cancer.
- You should not have had your bladder removed, have cancer in both kidneys, or have only one kidney.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a catheter-free method for delivering medication directly into the bladder. It may help patients with bladder pain, recurrent infections, bladder cancer, or cystitis after radiation or chemotherapy.
This trial tests a targeted therapy (disitamab vedotin, also called RC48) given directly into the bladder after surgery for HER2-positive upper tract urothelial cancer. The goal is to see if it helps prevent the cancer from coming back.
This study compares two approaches for people with intermediate-risk bladder cancer whose urine shows no signs of cancer after surgery. One group will be watched closely (active surveillance), while the other will receive chemotherapy directly into the bladder (intravesical chemotherapy). The goal is to see if surveillance alone can prevent unnecessary treatment while keeping the cancer controlled.
This trial tests whether putting chemotherapy medicine directly into the bladder right after surgery helps prevent bladder cancer from coming back. It compares gemcitabine versus epirubicin given as an immediate bladder “wash-in.”
This study uses a special ultrasound technique to take detailed pictures of the tiny blood vessels around bladder cancer. The goal is to help doctors better understand the cancer before surgery to remove the bladder.
This trial tests whether adding targeted radiation therapy to standard drug treatment can help people with urothelial cancer that has spread to a few spots (up to 3 outside the brain). If you are starting your first or second round of systemic therapy, this study may be an option.
Hear when a new Upper Urinary Tract Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.